U rinary incontinence is a distressing symptom that is a result of a combination of genitourinary pathology, age-related changes, and co-morbid conditions that impair normal micturition or the functional ability to toilet oneself or both. The prevalence of urinary incontinence is rising with the growth of an ageing population, making it imperative for clinicians to be well-versed with its management in both primary and secondary care. Urinary incontinence is classified into three main types: stress urinary incontinence, urge urinary incontinence, and mixed urinary incontinence. In this paper we discuss the assessment and management of urinary incontinence with a focus on community-based strategies.
Urinary incontinence (UI), defined by the International Continence Society as 'the complaint of any involuntary urinary leakage', is a common and significantly underreported symptom. Estimates suggest that approximately 3 500 000 women suffer from UI in the UK (Price & Currie, 2010) . It has been found to be second only to dementia as a trigger for residential or nursing home admission.
The prevalence of UI increases with age; it is usually low in young women, peaking around menopause. This is followed by a small decline between 60 and 70 years with a steady rise thereafter into later life. Although the prevalence of stress urinary incontinence (SUI) and mixed urinary incontinence (MUI) is higher than urgency urinary incontinence (UUI), the latter is more likely to impact are therefore significant areas to be borne in mind when dealing with a person with UI. Studies have shown that increased age, body mass index (BMI), parity, current smoking, type 2 diabetes mellitus, and hysterectomy are all associated with incontinence. UI is more common in Caucasian women than in Asian or African-Caribbean women (Danforth et al., 2006) . Apart from these, particularly in older people, continence requires mobility, manual dexterity, the cognitive ability to recognise and react to bladder filling, as well as the motivation to stay dry (see Box 1). A detailed history is useful to ascertain the aetiology and severity of the incontinence. Bladder diaries help to record filling and voiding cycles, and also provide valuable information regarding the patient's fluid intake, urinary frequency, urgency, diurnal variations, nocturnal cycles, functional bladder capacity, UI episodes and total urine output. Some diaries also record pad changes and trigger events to incontinence, thereby providing more information about type and severity of the UI. The National Institute for Health and Care Excellence (NICE) recommends use of bladder diaries (Table 2) for a minimum of 3 days, which includes a mixture of work and leisure days (NICE, 2013 function, social support, current coping mechanisms (e.g. use of continence pads, reduced fluid intake) and any medications that could contribute to the symptoms.
Physical examination and investigations are guided by history and presence/absence of symptomatic pelvic organ prolapse. Urine dipstick along with mid-stream urine (MSU) testing is advisable in all patients with symptomatic UI. UI can occur as a result of chronic retention (e.g. fibroids in females and prostatic hyperplasia in males), therefore checking for a palpable bladder and measuring a post-void residual urine volume is important.
Objective assessment of the amount of UI can be done using the pad test, in which an adsorbent pad is weighed before and after the leakage of urine giving an idea of the quantity of leakage. SUI can be identified by the cough stress test, where a patient with a comfortably full bladder is asked to cough in a supine or lithotomy position while the clinician checks for leakage. It can return a false negative result in up to 34% of cases (Haylen, Suthurst, & Frazer, 1989) .
Cystometry and urodynamics need not be performed in women with uncomplicated SUI or UUI before commencing conservative therapy. However, they may be useful in patients with mixed symptoms who could benefit from specific delineation of the cause of their urinary incontinence (Wood & Anger, 2014 For Qns 1 to 4: Do you leak urine (even small drops), wet yourself, wet your pads or undergarments . . .
None of the above

Rarely
Once in a while be mediated by the associated weight loss. There may be reduction in urgency episodes with caffeine reduction and smoking cessation.
Modification of fluid intake may help in patients with abnormally high or low fluid consumption (by altering the frequency of micturition in the former, and reducing the risk of urinary tract infections and constipation in the latter). Diuretics used solely for treatment of hypertension can be altered to other appropriate agents.
Pelvic floor muscle training There are various PMFT programmes recommended by different urogynaecology associations. NICE recommends at least eight contractions performed three times a day for at least 3 months duration as a first-line treatment for SUI and MUI. The duration of each contraction can be increased as tolerated to about 10 seconds.
Biofeedback can be a useful adjunct to ensure that the pelvic floor exercises are done properly. Biofeedback can be digital i.e. checking for muscle squeeze around the finger, resisting removal of a tampon, manometry to measure the pressure created in the vagina using intra- There are four types of pharmacological therapies available for UUI and overactive bladder (OAB) syndrome. These include oestrogen, anti-muscarinics, antidepressants and Botulinum toxin.
Local estrogen use is associated with overall subjective improvement in individuals with incontinence, fewer voids in 24 hours, fewer nocturnal voids, and less frequency and urgency (Cody, Richardson, & Moehrer, 2009) . It is therefore a useful agent in post-menopausal women with symptoms of UUI/OAB syndrome.
There are a considerable number of anti-cholinergic drug treatments for UUI/OAB such as oxybutynin, solifenacin, trospium, tolterodine and darifenacin (see Table 3 ). Most of the newer preparations are selective M2/M3 muscarinic receptor antagonists (Fig. 2) and have fewer side effects than nonselective drugs such as oxybutynin. NICE recommends oxybutynin or tolterodine, or once daily darifenacin as the first choice for women with OAB syndrome or MUI. Common side effects include dry mouth, constipation, heartburn, blurring of vision, tachycardia and flushing of skin. If not effective or well-tolerated, then other drugs (e.g. Solifenacin) or transdermal oxybutynin can be offered. Anti-cholinergic drugs should not be offered to women with symptoms of isolated SUI.
Mirabegron is a new drug approved by NICE in the management of refractory OAB syndrome. It activates beta-3 adrenergic receptors in the detrusor muscle, leading to muscle relaxation and increased bladder capacity. The usual dose of mirabegron is 50 mg once daily which should be reduced to 25 mg if estimated Glomerular Filtration Rate (eGFR) is less than 30 mL/min or in the event of hepatic impairment. Side effects include palpitations, tachycardia, dysuria, urinary tract infections and gastritis. It is contraindicated in severe hypertension.
Antidepressants such as imipramine are not recommended by NICE in the treatment of UI. For women with SUI, duloxetine may be offered as second-line therapy (after counselling with regards to adverse effects) if women prefer pharmacological to surgical treatment or are not suitable for surgical treatment.
Bladder wall injection with Botulinum toxin A can be offered to women with proven detrusor overactivity that has not responded to conservative management and drug therapy. A dose of 200 units is recommended; though this can be reduced to 100 units to minimise the risk of retention, but with a reduced success rate (NICE, 2013). .................................................................................................................................................................................................................................................. . ............................................................................................................................................................................................................................ Nerve stimulation to modulate reflex pathways can be used in severe cases of UUI and OAB syndrome. Sacral nerve stimulation is achieved through electrodes placed into the S3 nerve foramen either percutaneous (temporary), or surgically using a permanent lead. Posterior tibial nerve stimulation is technically less demanding and can be performed in an office setting. The posterior tibial nerve, which shares a common root (S2-S4) with innervation of the bladder, is stimulated using a needle electrode placed posterosuperior to the medial malleolus. The usual regime includes 12 weekly visits of 30 minutes each (Wood & Anger, 2014 Bulking agents, such as silicon particles, autologous fat, collagen or carbon beads, are injected near the bladder neck through a needle placed transurethrally or periurethrally. They can be useful in women who have failed to respond to non-invasive treatment and are unfit for surgery. Adverse effects include urinary tract infections, urinary retention, urgency and dysuria (Davila, 2011) .
Surgical procedures include slings and urethropexy. In recent years, midurethral slings have replaced pubovaginal slings as the gold standard for surgical correction of SUI (Wood & Anger, 2014) . Midurethral slings can be placed in an outpatient setting under local anaesthesia using either a retropubic (classic tension-free vaginal tape procedure) or a transobturator approach. In patients who fail tension-free procedures, re-adjustable slings can provide valuable ability to precisely alter sling tension to . ......................................................................................................................................................................................................... render the patient continent. The adjustable sling consists of a standard synthetic mesh sling combined with sutures that attach to an implantable tensioning device that resides permanently under the skin in the abdominal wall. Once implanted, this readjustable mechanical external device can be re-accessed under local anesthesia to fine-tune the sling should incontinence reappear months or years after the initial surgery (Errando et al., 2010) .
InnovAiT
Augmentation cystoplasty (using an intestinal segment) and ileal conduit diversion urostomy may be considered as a last resort in certain intractable cases, however, these procedures are now almost exclusively reserved for neurogenic causes (e.g. spinal cord injury) of UI. 
